Skip to main content
SpringerLink
Log in

Therapeutic switching of sulpiride, an anti-psychotic and prokinetic drug, to an anti-colitic drug using colon-specific drug delivery

  • Original Article
  • Published:
Drug Delivery and Translational Research Aims and scope Submit manuscript

Abstract

To test whether sulpiride (SP), an anti-psychotic and prokinetic drug, shows beneficial effects on experimental murine colitis, a colon-targeted prodrug of SP, 5-(aminoethanoylsulfamoyl)-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxybenzamide (glycylsulpiride (GSP)), was synthesized and its colonic delivery and therapeutic activity against 2,4-dinitrobenzenesulfonic acid (DNBS)–induced rat colitis were assessed. Synthesis of GSP was verified by infrared and proton nuclear magnetic resonance spectroscopy. GSP was converted to SP when incubated with the cecal contents but not when incubated with the small intestinal contents. The percent conversion was about 50.5% at 6 h and 67.7% at 10 h. Colonic delivery of GSP was examined by comparison with sulfasalazine (SSZ), a colon-specific prodrug of 5-aminosalicylic acid currently used for the treatment of inflammatory bowel disease. The two prodrugs accumulated similar concentrations of the corresponding parent drugs in the cecum at 2, 4, and 6 h after oral gavage. Although oral gavage of GSP released millimolar level of SP in the large intestine, SP was hardly detected in the blood. GSP improved colonic damage score and reduced myeloperoxidase activity up to 80.5% in the inflamed colon in a dose-dependent manner. Moreover, GSP was able to reduce the levels of inflammatory mediators in the inflamed colon. Overall, the anti-colitic effectiveness of GSP and SSZ was similar. In conclusion, colonic delivery of SP ameliorates DNBS-induced colitis in rats with no significant systemic absorption of SP. Thus, colon-targeted SP may be therapeutically switched to an anti-colitic drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347(6):417–29. https://doi.org/10.1056/NEJMra020831.

    Article  CAS  PubMed  Google Scholar 

  2. Bielefeldt K, Davis B, Binion DG. Pain and inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(5):778–88. https://doi.org/10.1002/ibd.20848.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Hugot JP, Zouali H, Lesage S, Thomas G. Etiology of the inflammatory bowel diseases. Int J Color Dis. 1999;14(1):2–9.

    Article  CAS  Google Scholar 

  4. Ko JK, Auyeung KK. Inflammatory bowel disease: etiology, pathogenesis and current therapy. Curr Pharm Des. 2014;20(7):1082–96.

    Article  CAS  Google Scholar 

  5. Lofberg R. Review article: medical treatment of mild to moderately active Crohn’s disease. Aliment Pharmacol Ther. 2003;17(Suppl 2):18–22.

    Article  PubMed  Google Scholar 

  6. Lee Y, Kim H, Kim W, Yoon JH, Jeong SH, Jung Y. Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis. J Drug Target. 2012;20(6):524–34. https://doi.org/10.3109/1061186X.2012.693498.

    Article  CAS  PubMed  Google Scholar 

  7. Jung Y, Kim YM. What should be considered on design of a colon-specific prodrug? Expert Opin Drug Deliv. 2010;7(2):245–58. https://doi.org/10.1517/17425240903490401.

    Article  CAS  PubMed  Google Scholar 

  8. Sinha VR, Kumria R. Colonic drug delivery: prodrug approach. Pharm Res. 2001;18(5):557–64.

    Article  CAS  PubMed  Google Scholar 

  9. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci. 2003;6(1):33–66.

    CAS  PubMed  Google Scholar 

  10. Peppercorn MA. Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development. Ann Intern Med. 1984;101(3):377–86.

    Article  CAS  PubMed  Google Scholar 

  11. Klotz U, Maier K, Fischer C, Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn’s disease. N Engl J Med. 1980;303(26):1499–502. https://doi.org/10.1056/NEJM198012253032602.

    Article  CAS  PubMed  Google Scholar 

  12. Kim W, Lee Y, Jeong S, Nam J, Lee S, Jung Y. Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective COX-2 inhibitor as an anti-colitic agent. Arch Pharm Res. 2015;38(10):1830–8. https://doi.org/10.1007/s12272-015-0602-y.

    Article  CAS  PubMed  Google Scholar 

  13. Mucci A, Nolfe G, Maj M. Levosulpiride: a review of its clinical use in psychiatry. Pharmacol Res. 1995;31(2):95–101.

    Article  CAS  PubMed  Google Scholar 

  14. Mansi C, Savarino V, Vigneri S, Perilli D, Melga P, Sciaba L, et al. Gastrokinetic effects of levosulpiride in dyspeptic patients with diabetic gastroparesis. Am J Gastroenterol. 1995;90(11):1989–93.

    CAS  PubMed  Google Scholar 

  15. Desai JK, Parmar NS. Gastric and duodenal anti-ulcer activity of sulpiride, a dopamine D2 receptor antagonist, in rats. Agents Actions. 1994;42(3–4):149–53.

    Article  CAS  PubMed  Google Scholar 

  16. Kawano M, Takagi R, Kaneko A, Matsushita S. Berberine is a dopamine D1- and D2-like receptor antagonist and ameliorates experimentally induced colitis by suppressing innate and adaptive immune responses. J Neuroimmunol. 2015;289:43–55. https://doi.org/10.1016/j.jneuroim.2015.10.001.

    Article  CAS  PubMed  Google Scholar 

  17. Terai H, Shimahara M. Chronic tongue ulceration resolved by sulpiride: a report of two cases. Clin Exp Dermatol. 2009;34(5):e40–2. https://doi.org/10.1111/j.1365-2230.2008.03110.x.

    Article  CAS  PubMed  Google Scholar 

  18. Arakawa T, Watanabe T, Tanigawa T, Tominaga K, Fujiwara Y, Morimoto K. Quality of ulcer healing in gastrointestinal tract: its pathophysiology and clinical relevance. World J Gastroenterol. 2012;18(35):4811–22. https://doi.org/10.3748/wjg.v18.i35.4811.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Lee S, Lee Y, Kim W, Nam J, Jeong S, Yoo JW, et al. Evaluation of glycine-bearing celecoxib derivatives as a colon-specific mutual prodrug acting on nuclear factor-kappaB, an anti-inflammatory target. Drug Des Devel Ther. 2015;9:4227–37. https://doi.org/10.2147/DDDT.S88543.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Kim W, Nam J, Lee S, Jeong S, Jung Y. 5-Aminosalicylic acid azo-linked to procainamide acts as an anticolitic mutual prodrug via additive inhibition of nuclear factor kappaB. Mol Pharm. 2016;13(6):2126–35. https://doi.org/10.1021/acs.molpharmaceut.6b00294.

    Article  CAS  PubMed  Google Scholar 

  21. Barone M, Chain F, Sokol H, Brigidi P, Bermudez-Humaran LG, Langella P, et al. A versatile new model of chemically induced chronic colitis using an outbred murine strain. Front Microbiol. 2018;9:565. https://doi.org/10.3389/fmicb.2018.00565.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Yano H, Hirayama F, Kamada M, Arima H, Uekama K. Colon-specific delivery of prednisolone-appended alpha-cyclodextrin conjugate: alleviation of systemic side effect after oral administration. J Control Release. 2002;79(1–3):103–12.

    Article  CAS  PubMed  Google Scholar 

  23. Walash MI, Kh Sharaf El-Din MM, El-Enany NM, Eid MI, Shalan SM. Simultaneous determination of sulpiride and mebeverine by HPLC method using fluorescence detection: application to real human plasma. Chem Cent J. 2012;6:13. https://doi.org/10.1186/1752-153X-6-13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Dong E, Nelson M, Grayson DR, Costa E, Guidotti A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc Natl Acad Sci U S A. 2008;105(36):13614–9. https://doi.org/10.1073/pnas.0805493105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Bressolle F, Bres J, Faure-Jeantis A. Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans. J Pharm Sci. 1992;81(1):26–32.

    Article  CAS  PubMed  Google Scholar 

  26. Rossi F, Forgione A. Pharmacotoxicological aspects of levosulpiride. Pharmacol Res. 1995;31(2):81–94.

    Article  CAS  PubMed  Google Scholar 

  27. Abdul Rani R, Raja Ali RA, Lee YY. Irritable bowel syndrome and inflammatory bowel disease overlap syndrome: pieces of the puzzle are falling into place. Intest Res. 2016;14(4):297–304. https://doi.org/10.5217/ir.2016.14.4.297.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Lanfranchi GA, Bazzocchi G, Marzio L, Campieri M, Brignola C. Inhibition of postprandial colonic motility by sulpiride in patients with irritable colon. Eur J Clin Pharmacol. 1983;24(6):769–72.

    Article  CAS  PubMed  Google Scholar 

  29. Komarov FI, Rapoport SI, Ivanov SV, Kharaian LV, Kolesnikov DB, Kurikov AV. Sulpiride treatment of irritable colon syndrome. Klin Med (Mosk). 2000;78(7):22–6.

    CAS  Google Scholar 

Download references

Funding

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2018R1D1A3B07045694).

Author information

Author notes

  1. Dohoon Kim and Wooseong Kim contributed equally to this work.

Authors and Affiliations

  1. College of Pharmacy, Pusan National University, Pusan, 609-735, Republic of Korea

    Dohoon Kim, Wooseong Kim, Seongkeun Jeong, Dayoon Kim, Jin-Wook Yoo & Yunjin Jung

Authors
  1. Dohoon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wooseong Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seongkeun Jeong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dayoon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jin-Wook Yoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yunjin Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yunjin Jung.

Ethics declarations

The animal protocol used in this study was reviewed and approved by the Pusan National University—Institutional Animal Care and Use Committee (Approval number: PNU-2017-1525; Approval date: 2017-04-19) for ethical procedures and scientific care. All institutional and national guidelines for the care and use of laboratory animals were followed.

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

ESM 1

(PDF 434 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, D., Kim, W., Jeong, S. et al. Therapeutic switching of sulpiride, an anti-psychotic and prokinetic drug, to an anti-colitic drug using colon-specific drug delivery. Drug Deliv. and Transl. Res. 9, 334–343 (2019). https://doi.org/10.1007/s13346-018-00599-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13346-018-00599-7

Keywords

Search

Navigation